Hansa Biopharma Presents Positive Outcomes Of Study Of Imlifidase In Kidney Transplantation
RefinitivLess than 1 min read
Hansa Biopharma AB 
HNSA:
PRESENTS POSITIVE OUTCOMES OF FIVE-YEAR FOLLOW-UP STUDY OF IMLIFIDASE IN KIDNEY TRANSPLANTATION AT ESOT CONGRESS 2025 IN LONDON
© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html
Login or create a forever free account to read this news